Objectives: To explore whether the duration of in vitro simulated antibiotic exposure influences bacterial resistance, time-dependent amplification of resistant subpopulations of Staphylococcus aureus was studied in 10 day simulations in a dynamic model with daptomycin as a prototypic agent.
Introduction
In vitro dynamic models have become common tools in bacterial resistance studies designed to predict optimal antibiotic dosing regimens. 1 Using these models, the amplification of resistant mutants and/or the concomitant loss in susceptibility was related to the ratio of the 24 h area under the concentration -time curve (AUC 24 ) to the MIC. Bell-shaped AUC 24 /MIC relationships with resistance have been established for fluoroquinolones, 2 -5 lipopeptides and glycopeptides. 6 These relationships allow prediction of AUC 24 /MIC ratios that protect against the enrichment of resistant mutants, i.e. 'anti-mutant' ratios. The robustness of these predictions is influenced by many factors including the duration of simulated treatments. 1, 2 Typically, bacterial resistance becomes more pronounced during treatment: greater numbers of resistant mutants are seen with longer treatments. 2, 7 A similar trend was demonstrated recently by Tam et al., 8 in long-term in vitro simulations with Staphylococcus aureus exposed to garenoxacin pharmacokinetics for 10 days.
The aim of the present study was to examine the impact of duration of treatment with or exposure to subtherapeutic daptomycin concentrations on: (i) the rate and extent of amplification of resistant S. aureus mutants; and (ii) the prediction of the antimutant AUC 24 /MIC ratio. To ensure enrichment of the resistant staphylococci, target AUC 24 /MIC ratios were designed to provide daptomycin concentrations above the MIC but below the mutant prevention concentration (MPC), i.e. within the mutant selection window (MSW) 9 over all or most of the dosing interval.
Materials and methods

Antimicrobial agent, bacterial strain, and MIC and MPC determination
Daptomycin was kindly provided by Cubist Pharmaceuticals, Inc.
(Lexington, MA, USA). A methicillin-resistant S. aureus strain ATCC 43300 was selected for the study. Susceptibility testing was performed in triplicate by broth microdilution techniques at 24 h post-exposure with the organism grown in Mueller-Hinton broth (MHB) at an inoculum size of 5Â10 5 cfu/mL. Because daptomycin antimicrobial activity is influenced by the presence of Ca 2þ , 10 MHB supplemented with 50 mg/L of calcium was used for all susceptibility studies. The MIC of daptomycin was estimated at 0.2 mg/L.
The MPC was determined as described elsewhere. 9 Briefly, the tested microorganism was cultured in MHB and incubated for 24 h. Then, the suspension was centrifuged (4000 g for 10 min) and resuspended in MHB to yield a concentration of 10 11 cfu/mL. A series of Mueller -Hinton II agar (MHA II) plates containing known antibiotic concentrations was then inoculated with $10 11 cfu/mL of S. aureus. The inoculated plates were incubated for 48 h at 378C and screened visually for growth. To estimate the MPC, logarithms of bacterial numbers were plotted against antibiotic concentrations. The MPC, taken as the point where the plot intersects the theoretical limit of detection (log cfu/mL¼ 1), was estimated at 12.5 mg/L.
Simulated pharmacokinetic profiles and their verification
Mono-exponential concentration decays of daptomycin (as a single dose) were simulated for 10 consecutive days at a half-life of 9 h, in accordance with values reported in humans. 11, 12 The simulated AUC 24 /MIC ratios were 32 and 64 h, which correspond to daptomycin concentrations within the MSW for 65% and 100% of the dosing interval, respectively.
To verify the reliability of pharmacokinetic simulations, actual antibiotic concentrations were compared with the target concentrations in a series of single-dose experiments that simulate monoexponential elimination of daptomycin (initial concentration of 4.4 mg/mL, n¼ 3). The central compartment was sampled 0.5, 1, 2, 4, 8, 12 and 24 h after antibiotic administration.
Daptomycin concentrations were determined by an HPLC assay. Isocratic separation was performed at 428C on a Nucleosil 100 C18 column (40 mmÂ4.6 mm, particle size 3 mm; Macherey-Nagel & Co, Germany). The injection volume was 20 mL. The mobile phase consisted of a 0.02 mM solution of monobasic potassium phosphate and acetonitrile (volume ratio 66:34) at a flow rate of 1.4 mL/min (Gilson 305, Gilson S.A.S., Villiers-le-Bel, France). The column effluent was monitored at 230 nm UV (Waters 481, Waters Associates, Milford, MA, USA). The calibration plot was linear (r 2 !0.99) over the concentration range of 0.15-10 mg/L. The within-run relative standard deviations (n¼5) for daptomycin quality control concentrations of 10, 1.5 and 0.15 mg/L were 1.7%, 3.1% and 5.9%, respectively. The lower limit of accurate detection was 0.05 mg/L.
The determined concentrations of daptomycin were in concordance with the target values (r 2 ¼ 0.98), without systematic differences over the entire observation period. The estimated half-life of daptomycin (8 h) was close to the target value (9 h).
In vitro dynamic model
A previously described dynamic model was used in this study. 6 Briefly, the model consisted of two connected flasks, one containing fresh MHB supplemented with 50 mg/L of calcium and the other with a magnetic stirrer, the central unit, with the same broth containing either a bacterial culture alone or a bacterial culture plus antibiotic. Peristaltic pumps circulated fresh nutrient medium to the flasks and from the 60 mL central unit at a flow rate of 4.6 mL/h with daptomycin. The system was filled with sterile MHB and placed in an incubator at 378C. The central unit containing 54 mL of fresh MHB was inoculated with 6 mL of an 18 h culture of S. aureus (10 9 cfu/mL). After a 30 min incubation, daptomycin was injected into the central unit. Each experiment was performed in duplicate.
Quantification of the antimicrobial effect and susceptibility changes
In each experiment, multiple sampling of bacteria-containing medium from the central compartment was performed throughout the observation period. Samples were serially diluted as appropriate, and 100 mL was plated onto MHA II plates. The duration of the experiments was defined in each case as the time after the last dose until antibiotic-exposed bacteria reached the maximum numbers observed in the absence of antibiotic ($10 9 cfu/mL). The lower limit of accurate detection was 10 2 cfu/mL. To reveal possible changes in susceptibility during treatment, MICs for bacterial cultures sampled from the model were determined daily for 10 days using the method described above. Also, each sample was plated onto agar plates containing 2Â and 4Â the MIC of daptomycin. The lower limit of detection was 10 cfu/mL.
Based on time-kill data and population analysis data, areas under the bacterial kinetic curves (AUBCs) 13 and under the bacterial mutant kinetic curves (AUBC M s), 14 respectively, were determined from the beginning to the end of the treatment, i.e. to 240 h. In addition, AUBC and AUBC M from time zero to different times (t) after the start of the treatment, i.e. AUBC(t) and AUBC M (t), were calculated. To compare daptomycin effects on the susceptible and resistant subpopulations, AUBC(t) and AUBC M (t) were corrected for the different detection limits by subtracting areas of the figures limited from above by the level of 10 2 cfu/mL (susceptible subpopulation) and 10 cfu/mL (resistant subpopulation).
Time courses of the corrected AUBC(t) were fitted by a linear equation:
where Y is AUBC(t), Y 0 is the minimal value of Y, x is t and a is a parameter. Time courses of the corrected AUBC M (t) were fitted by a polynomial equation:
where Y is AUBC M (t), Y 0 is the minimal value of Y, x is t and a and b are parameters.
To study the possible effects of duration of the treatment and the length of the observation period on the AUC 24 /MIC -resistance relationships, different fragments of the time courses of resistant mutants reported from earlier studies that exposed S. aureus in vitro to 5 day treatments with daptomycin 6 and 10 day treatments with garenoxacin 8 were quantified using the AUBC M parameter as if the observations had been stopped earlier than they actually were. Based on data reported in the daptomycin study, 6 the AUBC M s were determined with truncated curves, i.e. from the start of treatment (time zero) to 3 days, from 0 to 4 days, and with the entire time courses, i.e. from 0 to 5 days. Based on data reported in the garenoxacin study, 8 the AUBC M s were determined from 0 to 4 days, from 0 to 6 days, from 0 to 8 days and from 0 to 10 days. Each estimated AUBC M was related to the simulated AUC 24 /MIC ratios using a Gaussian-type function:
where Y is AUBC M , Y 0 is the minimal value of Y, x is AUC 24 /MIC, x 0 is AUC 24 /MIC that corresponds to the maximal value of AUBC M , and a and b are parameters.
Results
Simulated pharmacokinetic profiles of daptomycin and the time courses of daptomycin-exposed S. aureus ATCC 43300 grown on antibiotic-free (0Â the MIC) and antibiotic-containing media (2Â and 4Â the MIC) are shown in Figure 1 . As expected from the MSW considerations, daptomycin-resistant mutants were enriched at both AUC 24 /MIC ratios. According to the population analysis data, this enrichment appeared soon after the start of treatments, with a gradual increase in numbers of resistant mutants over the entire treatment period. The resistant mutants were amplified by 3 -4 log cfu/mL on the third day, by 4.5 -5.5 log cfu/mL on the fifth day and by 7-8 log cfu/mL on the 10th day, when their numbers ($10 7 -10 8 cfu/mL) approached those observed with susceptible organisms ($10 9 cfu/mL). Significant enrichment of daptomycin-resistant mutants occurred even after 3-5 days of antibiotic exposure.
The gradual replacement of susceptible bacteria with resistant subpopulations is illustrated by the AUBC(t) and AUBC M (t) data ( Figure 2 ). As seen in the figure, at both simulated AUC 24 /MIC ratios the time courses of the numbers of mutants resistant to 4Â the MIC of daptomycin differed from the total population in that they were exponential rather than linear relationships. As a result, the AUBC M (t) to AUBC(t) ratio increased gradually during the treatments. For example, on the 10th day this ratio was 2.2-to 2.5-fold greater than on the thirrd day: 0.54-0.55 versus 0.22-0.25. Similar patterns were inherent in the AUBC M (t) -time relationships observed with mutants resistant to 2Â the MIC of daptomycin (data not shown).
This enrichment with resistant mutants was accompanied by a concomitant loss in daptomycin susceptibility, up to 17-fold with the AUC 24 /MIC of 32 h and 13-fold with the AUC 24 /MIC of 64 h. However, time courses of daptomycin MICs for the cultures ( Figure 3 ) were more erratic than those of the AUBC M . As seen in the figure, the most pronounced loss in susceptibility occurred during the first 5 days (up to 9-fold with both AUC 24 /MICs). These steep MIC increases were followed by less pronounced changes toward the end of treatment. 
Discussion
Time-dependent amplification of resistant staphylococci was observed in simulations of 10 day treatments with daptomycin as a prototypic agent at subtherapeutic concentrations. Daptomycin-resistant mutants were selected as early as the second to third day after antibiotic exposure began, and they were further enriched exponentially with concomitant loss in susceptibility. These findings suggest that the extent of mutant selection depends on the duration of simulated exposure or treatment and on the length of the observation period. Earlier, similar conclusions were drawn from in vitro studies with fluoroquinolones 2,5 and with lipopeptides and glycopeptides using shorter 5 day treatments. 6 Based on such observations, Tam et al. 8 proposed that the duration of treatment might be critical for in vitro estimates of the anti-mutant AUC 24 /MIC ratio, i.e. the ratio that prevents amplification of resistant mutants and/or suppresses them. From this point of view, the majority of in vitro studies that simulate shorter antibiotic exposures might underestimate the true anti-mutant AUC 24 /MIC ratios. To explore whether this danger is real or apparent, we have reassessed resistance data reported from other studies 6, 8 by determining the AUBC M parameter over different treatment/observation periods. 
